Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
Infection. 2023 Jun;51(3):641-654. doi: 10.1007/s15010-022-01904-w. Epub 2022 Sep 14.
Infection. 2023.
PMID: 36104613
Free PMC article.
Clinical Trial.
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor.
Gatlik E, Mehes B, Voltz E, Sommer U, Tritto E, Lestini G, Liu X, Pal P, Velinova M, Denney WS, Fu Y, Opipari A, Dean D, Junge G.
Gatlik E, et al. Among authors: mehes b.
Clin Transl Sci. 2024 May;17(5):e13789. doi: 10.1111/cts.13789.
Clin Transl Sci. 2024.
PMID: 38761014
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite